Evidence map›Paper›PMID 38379566›Full record

ArticleOpen forum infectious diseases2024

Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Subvariant Neutralization Following a Primary Vaccine Series of NVX-CoV2373 and BNT162b2 Monovalent Booster Vaccine.

Tara M Babu, Xiaoying Shen, R Scott McClelland, Zijun Wang, Stacy Selke, Chloe Wilkens, Kirsten A Hauge, Christopher L McClurkan, Erin Goecker, Kerry J Laing and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Tara M BabuDepartment of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.ORCID https://orcid.org/0000-0001-7093-4077
Xiaoying ShenDepartment of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
R Scott McClellandDepartment of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
Zijun WangLaboratory of Molecular Immunology, The Rockefeller University, New York, New York, USA.
Stacy SelkeDepartment of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
Chloe WilkensDepartment of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
Kirsten A HaugeDepartment of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
Christopher L McClurkanDepartment of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
Erin GoeckerDepartment of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
Kerry J LaingDepartment of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
David M KoelleDepartment of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
Alexander L GreningerDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
Michel C NussenzweigLaboratory of Molecular Immunology, The Rockefeller University, New York, New York, USA.
David C MontefioriDepartment of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
Lawrence CoreyDepartment of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
Anna WaldDepartment of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.

Funding

LOC: HIV Vaccine Trials NetworkUM1AI068614 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Dan H. Barouch, Lawrence Corey · 2011 to 2026
$1175.6M
6 · The paper itself

Abstract

We evaluated the immunologic response to a novel vaccine regimen that included 2 doses of NVX-CoV2373 (Novavax) followed by 1 dose of BNT162b2 (Pfizer-BioNTech) monovalent booster vaccine. A durable neutralizing antibody response to Omicron BA.4/BA.5 and BA.1 variants was observed at month 6 after the booster, while immune escape was noted for the XBB.1.5 variant.

Indexed as

antibodySARS-CoV-2vaccinevirus

Identifiers

PMID38379566
PMCPMC10878050

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.